Welcome to our dedicated page for Rxsight news (Ticker: RXST), a resource for investors and traders seeking the latest updates and insights on Rxsight stock.
RxSight, Inc. (RXST) delivers groundbreaking light adjustable lens technology that transforms post-cataract surgery outcomes. This dedicated news hub provides investors and medical professionals with essential updates on the company's clinical advancements and strategic developments.
Access official press releases covering product innovations, financial performance, and regulatory milestones. Our curated collection includes updates on the Light Adjustable Lens system's clinical adoption, partnership announcements with leading ophthalmology centers, and research breakthroughs in customized vision correction.
Key areas of coverage include quarterly earnings reports, FDA clearances for new device iterations, and peer-reviewed study results validating LAL technology outcomes. Stay informed about manufacturing expansions and international market entries that demonstrate RXST's growth trajectory in the premium intraocular lens sector.
Bookmark this page for real-time updates on how RxSight continues to redefine cataract care through its unique post-operative adjustment capabilities. Monitor critical developments that position the company at the forefront of personalized ophthalmic solutions.
RxSight, Inc. (NASDAQ: RXST), a company focused on advanced ophthalmic medical devices, is set to present at the Bank of America Healthcare Conference on May 10, 2023, at 3:55 PM PT / 6:55 PM ET. The presentation will focus on their innovative RxSight® Light Adjustable Lens system, which enhances vision after cataract surgery by allowing adjustments post-operatively. This system includes the RxSight Light Adjustable Lens® and the Light Delivery Device (LDD™), marking it as the first adjustable intraocular lens technology available. Interested stakeholders can access the live and archived webcast of the presentation via the company’s investor relations website.
RxSight, Inc. (NASDAQ: RXST) announced that it will report its first quarter 2023 financial results on May 9, 2023, after market close. Management is set to discuss the results during a conference call beginning at 1:30 PM PT / 4:30 PM ET. This call aims to provide insights into the company’s financial performance and future outlook following their innovative advancements in ophthalmic medical devices, specifically their Light Adjustable Lens system designed for cataract surgery. The technology is unique as it allows for post-surgery adjustments to optimize patients' vision quality. Interested investors can register for the call and access it via a live and archived webcast.
RxSight, Inc. (NASDAQ: RXST) announced that its Light Adjustable Lens™ (LAL) system will feature in various surgeon presentations at the American Society of Cataract and Refractive Surgery (ASCRS) annual meeting in San Diego from May 5-8, 2023. Key topics include:
- Presbyopia Correction - Neda Shamie, MD on May 5.
- Small Aperture Technology Integration - Cathleen M. McCabe, MD on May 6.
- Corneal Astigmatism Outcomes - Multiple presenters on May 7.
Surgeons will also share their LAL experiences at RxSight's booth (#1911), with additional details available through their website. This technology is the only adjustable intraocular lens system, enhancing post-cataract surgery vision.
On April 5, 2023, RxSight, operating under the stock symbol RXST, announced its participation in the Needham Healthcare Conference. The management team will engage in a fireside chat on April 19, 2023, at 11:15 a.m. PT, accessible via a live and archived webcast on their investor relations website.
RxSight is an ophthalmic medical device company focused on enhancing vision after cataract surgery with its innovative RxSight Light Adjustable Lens system. This technology allows for custom adjustments post-surgery, providing patients with optimized visual outcomes. For more details, visit www.rxsight.com.
FAQ
What is the current stock price of Rxsight (RXST)?
What is the market cap of Rxsight (RXST)?
